Cheil Bio Co

Cheil Bio Co Financing Cash Flow

Delisted·Feb 25, 2026

The Net Financing Cash Flow of Cheil Bio Co (052670.KQ) as of Nov 17, 2026 is -336.39 M KRW. In the previous year, Net Financing Cash Flow was -39.91 M KRW — a change of 742.85% (lower).

Financing Cash Flow

-336.39 MKRW

YoY

742.85%

Last updated:

Net Financing Cash Flow of Cheil Bio Co is 2024 -336.39 M KRW. Net Financing Cash Flow of Cheil Bio Co was 2023 -39.91 M KRW. It decreases by 742.85% lower compared to the previous year.

The Cheil Bio Co Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2017
-4.99 B KRW
Jan 1, 2018
-2.52 B KRW
Jan 1, 2019
-58.57 M KRW
Jan 1, 2020
6.38 B KRW
Jan 1, 2021
-41.76 M KRW
Jan 1, 2022
-3.08 B KRW
Jan 1, 2023
-39.91 M KRW
Jan 1, 2024
-336.39 M KRW
The Cheil Bio Co Financing Cash Flow history
YEARFinancing Cash FlowYoY
-336.39 MKRW+742.85%
-39.91 MKRW-98.71%
-3.08 BKRW+7,283.28%
-41.76 MKRW-100.65%
6.38 BKRW-10,989.57%
-58.57 MKRW-97.68%
-2.52 BKRW-49.46%
-4.99 BKRW+196.14%
-1.68 BKRW-110.42%
16.16 BKRW-2,629.60%
-638.68 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cheil Bio Co Stock analysis

What does Cheil Bio Co do? Cheil Bio Co., Ltd. generates revenue through the production and sale of veterinary products for pigs, cattle, chickens, cows, and aquatic animals. The company offers antibiotics, antimicrobials, lactobacillus, enzyme preparations, parasiticides, antiseptics, organic trace minerals, vaccines, and diagnostic kits including ELISA test kits, virus test kits, and DNA kits. These products are primarily sold to the domestic market, targeting livestock farmers and veterinary clinics. The firm also provides feed additives as part of its product portfolio. The company's product range includes specialized solutions for cattle, pigs, chickens, pets, and other animals, with a focus on health management and disease prevention. Veterinary clinics and livestock farms form the core customer segments, purchasing antibiotics, vaccines, and diagnostic tools to maintain animal health. The domestic market remains the primary sales channel, with no mention of international distribution. Cheil Bio's offerings are designed to address common health challenges in livestock, such as infections and parasitic infestations, through both preventive and therapeutic products. The inclusion of diagnostic kits like ELISA and DNA tests supports advanced veterinary care, enhancing the company's value proposition for professional animal health providers. Cheil Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cheil Bio Co stock

Net Financing Cash Flow of Cheil Bio Co is -336.39 M KRW in 2024.

Net Financing Cash Flow of Cheil Bio Co changed from -39.91 M KRW to -336.39 M KRW, representing a 742.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Cheil Bio Co since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Cheil Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cheil Bio Co

All Key Metrics — Cheil Bio Co